Navigation Links
Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
Date:3/19/2013

erially from those we project.  Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product.  Further, preclinical results do not guarantee safe and effective performance of product candidates in humans.  The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models.  The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures.   Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market.  Our business may be impacted by government investigations, litigation and products liability claims.  If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions.  We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amgen Announces 2013 Second Quarter Dividend
2. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
3. Amgen Announces Webcast of 2012 Fourth Quarter and Full Year Financial Results
4. Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
5. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
6. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
7. Amgen Announces 2012 Third Quarter Dividend
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen to Acquire Micromet
10. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
11. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015 ReliantHeart, Inc., an innovative ... a supplier of precision transit-time flow measurement solutions, are ... improve the efficiency of the HeartAssist5® Left ... to experience greater mobility and peace of mind. ... flow board, will draw 1/6th of the power required ...
(Date:3/25/2015)... (PRWEB) March 26, 2015 Agnition announced ... episode of American Farmer, airing for the first time ... segment of American Farmer will explore the extremely important ... crop producers with a patented Microbial Catalyst™ technology that ... greater yields. The segment will air again on April ...
(Date:3/25/2015)... 2015 Laboratory workers can turn ... Analytical Balances to get best-performing features while still ... balances from the trusted brand include: , ... your efficiency by providing a large weighing surface ... modes include parts counting, percent weighing, checkweighing, animal/dynamic ...
(Date:3/25/2015)... March 25, 2015 Data from ... Mechanism of Action in Neuromuscular Diseases , ... Cytokinetics, Incorporated (Nasdaq: CYTK) announced the publication of ... troponin activator tirasemtiv in the journal Neurotherapeutics. ... “Evidence of Effect” or hypothesis-generating clinical trial which ...
Breaking Biology Technology:LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2New Economical Top-Loading and Analytical Symmetry Balances from Cole-Parmer 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
... Tekturna HCT combines first approved direct renin inhibitor with the ... - Data show combination of Tekturna and HCTZ resulted in significant ... patients are not at goal and most require two or more, ... ...
... CHICAGO, Jan. 18 Brinks Hofer Gilson & ... the United States, is,pleased to announce that 21 of ... in a survey conducted by Law & Politics magazine.,Additionally, ... Meredith Martin Addy, chair of the Appellate Group ...
... 18 Abbott (NYSE: ABT ),announced today it ... its fully automated HTLV-I/HTLV-II blood screening test,for use on ... use by,laboratories to screen individual donations of blood and ... I and/or human T --,lymphotropic virus Type II (anti-HTLV-I/HTLV-II)., ...
Cached Biology Technology:Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 2Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 3Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 4Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 5Twenty-One Brinks Hofer Gilson & Lione Attorneys Named 2008 'Illinois Super Lawyers' 2Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II 2Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II 3
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Latin America . Annual estimates ...
(Date:3/17/2015)... , March 17, 2015 Emotient, the ... software, today announced general availability of Emotient ... for the analysis of facial expressions. The system ... media content, products and services. It delivers audience ... and sentiment - as derived from facial evidence ...
(Date:3/12/2015)... WINSTON-SALEM, N.C. , March 12, 2015 ... afternoon at Brenner Children,s Hospital, part of Wake Forest ... an outreach initiative for the 2015 ACC Men,s Basketball ... taking pictures with them and getting their autographs. ... Wake Forest Baptist. It is the only children,s hospital ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... EUREKA project E! 3025 MONALISA has developed a new, completely ... as growth promoters and to prevent the damaging effects of ... have been prohibited for use in animal feed in the ... effective antimycotoxic agent. The already-known capacity of clay minerals to ...
... massive humpbacks glide through the sea with ease to the ... excavated the equations behind a variety of complex phenomena. ... working closely with a team of Harvard evolutionary biologists led ... icon of evolution: the beaks of Darwin,s finches. In ...
... Thanks to the introduction of various non-native species ... feral animals. A new application developed by ecologists at ... first issue of Methods in Ecology and Evolution ... aims to improve the success of wildlife managers tasked ...
Cached Biology News:French and Spanish researchers develop a natural alternative to antibiotics in animal feed 2French and Spanish researchers develop a natural alternative to antibiotics in animal feed 3Simple math explains dramatic beak shape variation in Darwin's finches 2Simple math explains dramatic beak shape variation in Darwin's finches 3Killing in the name of conservation 2
... EVO384R are fast multi-channel pipetting platforms consisting ... sizes, with a multi-channel head and a ... saving, with true parallel processing of sample ... assays with the Freedom EVOware program. ...
... General description: Aminopropylsilane ... commonly used slide chemistry ... APS Coated Slides for ... reliable glass substrate for ...
Collected from animals that are 16 to 18 months old. Sterile, Cell culture tested, ID clarifier: USA Origin...
... (CYP450) metabolite postulated to play an autacoid ... In rat cerebral microvessels, 20-HETE is a ... is excreted mainly as the glucuronide conjugate. ... in human urine) is about 10-fold lower ...
Biology Products: